

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
30 March 2023 (30.03.2023)



(10) International Publication Number
WO 2023/049475 A1

(51) International Patent Classification:

C12N 15/113 (2010.01) A61P 1/16 (2006.01)
A61K 31/7088 (2006.01) A61P 11/00 (2006.01)

(21) International Application Number:

PCT/US2022/044765

(22) International Filing Date:

26 September 2022 (26.09.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/248,520 26 September 2021 (26.09.2021) US
PCT/US2021/058495

08 November 2021 (08.11.2021) US

63/331,756 15 April 2022 (15.04.2022) US

63/397,320 11 August 2022 (11.08.2022) US

(71) Applicant: **WAVE LIFE SCIENCES LTD.** [SG/SG]; 7
Straits View #12-00, Marina One East Tower, Singapore
018936 (SG).

(72) Inventors; and

(71) Applicants (for US only): **MONIAN, Prashant** [IN/US];
c/o WAVE LIFE SCIENCES LTD., 733 Concord Avenue,
Cambridge, Massachusetts 02138 (US). **SHIVALILA,
Chikdu Shakti** [US/US]; c/o WAVE LIFE SCIENCES
LTD., 733 Concord Avenue, Cambridge, Massachusetts
02138 (US). **LU, Genliang** [US/US]; c/o WAVE LIFE
SCIENCES LTD., 733 Concord Avenue, Cambridge, Mass-
achusetts 02138 (US). **VARGESE, Chandra** [US/US]; c/
o WAVE LIFE SCIENCES LTD., 733 Concord Avenue,
Cambridge, Massachusetts 02138 (US). **GIANGRANDE,
Paloma Hoban** [US/US]; c/o WAVE LIFE SCIENCES
LTD., 733 Concord Avenue, Cambridge, Massachusetts
02138 (US). **KANDASAMY, Pachamuthu** [US/US]; c/
o WAVE LIFE SCIENCES LTD., 733 Concord Ave-
nue, Cambridge, Massachusetts 02138 (US). **IWAMO-
TO, Naoki** [JP/US]; c/o WAVE LIFE SCIENCES LTD.,
733 Concord Avenue, Cambridge, Massachusetts 02138
(US). **SHIMIZU, Mamoru** [JP/US]; c/o WAVE LIFE
SCIENCES LTD., 733 Concord Avenue, Cambridge, Mass-
achusetts 02138 (US). **YU, Hui** [US/US]; c/o WAVE
LIFE SCIENCES LTD., 733 Concord Avenue, Cambridge,
Massachusetts 02138 (US). **YANG, Hailin** [US/US]; c/
o WAVE LIFE SCIENCES LTD., 733 Concord Avenue,
Cambridge, Massachusetts 02138 (US). **LAMORE, Sarah
Diane** [US/US]; c/o WAVE LIFE SCIENCES LTD., 733
Concord Avenue, Cambridge, Massachusetts 02138 (US).

ZHANG, Fengjiao [CN/US]; c/o WAVE LIFE SCIENCES
LTD., 733 Concord Avenue, Cambridge, Massachusetts
02138 (US). **NARAYANAN, Padmakumar** [US/US]; c/
o WAVE LIFE SCIENCES LTD., 733 Concord Avenue,
Cambridge, Massachusetts 02138 (US).

(74) Agent: **LI, Xiaodong** et al.; CHOATE, HALL & STE-
WART LLP, Two International Place, Boston, Massachu-
setts 02110 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))

(54) Title: OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF

(57) Abstract: Among other things, the present disclosure provides designed oligonucleotides and compositions thereof. In some embodiments, oligonucleotides and compositions of the present disclosure can provide high levels of adenosine editing. In some embodiments, oligonucleotides and compositions of the present disclosure are useful for treating various conditions, disorders or diseases, e.g., alpha-1 antitrypsin deficiency. In some embodiments, the present disclosure provides methods for treating various conditions, disorders or diseases that can benefit from adenosine editing.

WO 2023/049475 A1